TN2018000130A1 - N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases - Google Patents
N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseasesInfo
- Publication number
- TN2018000130A1 TN2018000130A1 TNP/2018/000130A TN2018000130A TN2018000130A1 TN 2018000130 A1 TN2018000130 A1 TN 2018000130A1 TN 2018000130 A TN2018000130 A TN 2018000130A TN 2018000130 A1 TN2018000130 A1 TN 2018000130A1
- Authority
- TN
- Tunisia
- Prior art keywords
- sub
- benzylpiperidin
- pyrazin
- piperazine
- antagonists
- Prior art date
Links
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title abstract 3
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title abstract 3
- NTEFDRIAFGEYBB-UHFFFAOYSA-N N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-pyrazin-2-ylpiperazine-1-carboxamide Chemical class C(C1=CC=CC=C1)N1CCC(CC1)CCNC(=O)N1CCN(CC1)C1=NC=CN=C1 NTEFDRIAFGEYBB-UHFFFAOYSA-N 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- -1 small molecule compounds Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562252179P | 2015-11-06 | 2015-11-06 | |
| US201662275708P | 2016-01-06 | 2016-01-06 | |
| PCT/US2016/060659 WO2017079641A1 (en) | 2015-11-06 | 2016-11-04 | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2018000130A1 true TN2018000130A1 (en) | 2019-10-04 |
Family
ID=57349137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2018/000130A TN2018000130A1 (en) | 2015-11-06 | 2016-11-04 | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11033539B2 (https=) |
| EP (1) | EP3371164B1 (https=) |
| JP (2) | JP6917989B2 (https=) |
| KR (1) | KR20180073685A (https=) |
| CN (1) | CN108349936B (https=) |
| AU (1) | AU2016348524B2 (https=) |
| BR (1) | BR112018008630A2 (https=) |
| CA (1) | CA3001873A1 (https=) |
| CL (1) | CL2018001217A1 (https=) |
| CO (1) | CO2018004800A2 (https=) |
| ES (1) | ES2915266T3 (https=) |
| HK (1) | HK1253029A1 (https=) |
| IL (1) | IL258862B (https=) |
| MA (1) | MA43168A (https=) |
| MX (1) | MX386148B (https=) |
| MY (1) | MY194461A (https=) |
| PE (1) | PE20181010A1 (https=) |
| PH (1) | PH12018500940A1 (https=) |
| SA (1) | SA518391518B1 (https=) |
| SG (1) | SG11201803757UA (https=) |
| TN (1) | TN2018000130A1 (https=) |
| WO (1) | WO2017079641A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3371164B1 (en) * | 2015-11-06 | 2022-03-16 | Neurocrine Biosciences, Inc. | N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
| ES2808920T3 (es) | 2015-11-06 | 2021-03-02 | Hoffmann La Roche | Derivados de indolin-2-ona |
| US12600726B2 (en) | 2017-07-12 | 2026-04-14 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| AU2018313802A1 (en) | 2017-08-08 | 2020-02-20 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2019079410A1 (en) | 2017-10-17 | 2019-04-25 | Vanderbilt University | ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4 |
| IL310346A (en) | 2017-10-20 | 2024-03-01 | Univ Vanderbilt | Muscarinic acetylcholine M4 receptor antagonists |
| AU2018360581A1 (en) | 2017-10-31 | 2020-06-11 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| EP3732163A4 (en) | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS |
| CN111788182B (zh) * | 2018-02-02 | 2023-09-26 | 范德堡大学 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| US12054487B2 (en) | 2018-09-04 | 2024-08-06 | Contineum Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| IL325201A (en) * | 2019-06-17 | 2026-02-01 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of using them |
| KR20220100860A (ko) * | 2019-09-17 | 2022-07-18 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 질병의 치료에 사용하기 위한 치환된, 포화 및 불포화 n-헤테로시클릭 카르복사미드 및 관련 화합물 |
| IL326597A (en) | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic M1 acetylcholine receptor antagonists |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| EP4069367B1 (en) | 2019-12-06 | 2024-05-15 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| CN111072551A (zh) * | 2019-12-30 | 2020-04-28 | 上海睿瓦科技有限公司 | 催化氢化一步法制取哌啶胺的方法 |
| EP4100410B1 (en) * | 2020-02-05 | 2026-04-22 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| WO2022156708A1 (en) * | 2021-01-20 | 2022-07-28 | Jacobio Pharmaceuticals Co., Ltd. | Parp7 enzyme inhibitor |
| AU2022289728A1 (en) * | 2021-06-11 | 2023-11-16 | Neuronascent, Inc. | Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type |
| CN118076585A (zh) * | 2021-07-23 | 2024-05-24 | 国家医疗保健研究所 | 革兰氏阴性菌外排泵抑制剂 |
| WO2023010078A1 (en) * | 2021-07-30 | 2023-02-02 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| JP2025539787A (ja) * | 2022-11-16 | 2025-12-09 | ヴァーンウィ セラピューティクス，インコーポレイテッド | Ｔｙｋ２阻害剤 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0619814A1 (en) * | 1991-12-31 | 1994-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| GB9313201D0 (en) * | 1993-06-25 | 1993-08-11 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| US5700801A (en) | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| IL135488A0 (en) * | 1997-11-18 | 2001-05-20 | Teijin Ltd | Cyclic amine derivatives |
| DE60023878T2 (de) * | 1999-05-18 | 2006-07-20 | Teijin Ltd. | Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen |
| HK1043590A1 (zh) * | 1999-09-22 | 2002-09-20 | Schering Corporation | 毒蕈碱性拮抗物 |
| US20070010509A1 (en) * | 1999-12-08 | 2007-01-11 | Tatsuki Shiota | Cycloamine ccr5 receptor antagonists |
| US6410566B1 (en) * | 2000-05-16 | 2002-06-25 | Teijin Limited | Cyclic amine derivatives and their use as drugs |
| JPWO2003062234A1 (ja) * | 2002-01-23 | 2005-05-19 | 山之内製薬株式会社 | キノキサリン化合物 |
| US8673924B2 (en) * | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| BR0317230A (pt) | 2002-12-13 | 2005-10-25 | Smithkline Beecham Corp | Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| WO2007007282A2 (en) * | 2005-07-11 | 2007-01-18 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as muscarinic receptor antagonists |
| JP2009521448A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ |
| WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| EP1997805A1 (en) * | 2007-06-01 | 2008-12-03 | Commissariat à l'Energie Atomique | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans |
| JP2013028538A (ja) * | 2009-11-13 | 2013-02-07 | Dainippon Sumitomo Pharma Co Ltd | 新規アミド誘導体 |
| IN2014CN04671A (https=) | 2011-11-25 | 2015-09-18 | Nerviano Medical Sciences Srl | |
| US20150259649A1 (en) * | 2012-11-08 | 2015-09-17 | Emory University | Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto |
| CN104812387A (zh) * | 2012-11-20 | 2015-07-29 | 霍夫曼-拉罗奇有限公司 | 取代的1,6-萘啶 |
| AU2014233757B2 (en) | 2013-03-18 | 2017-12-21 | Genoscience Pharma | Quinolines derivatives as novel anticancer agents |
| JP6272832B2 (ja) | 2013-04-04 | 2018-01-31 | 武田薬品工業株式会社 | 複素環化合物 |
| US9611223B2 (en) * | 2013-09-11 | 2017-04-04 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| MX2016012208A (es) * | 2014-03-20 | 2017-01-26 | Samumed Llc | Indazol-3-carboxamidas 5-substituidas y preparacion y uso de las mismas. |
| EP3371164B1 (en) * | 2015-11-06 | 2022-03-16 | Neurocrine Biosciences, Inc. | N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
-
2016
- 2016-11-04 EP EP16798333.7A patent/EP3371164B1/en active Active
- 2016-11-04 CN CN201680064834.6A patent/CN108349936B/zh active Active
- 2016-11-04 JP JP2018522553A patent/JP6917989B2/ja active Active
- 2016-11-04 TN TNP/2018/000130A patent/TN2018000130A1/en unknown
- 2016-11-04 KR KR1020187015620A patent/KR20180073685A/ko not_active Ceased
- 2016-11-04 SG SG11201803757UA patent/SG11201803757UA/en unknown
- 2016-11-04 MA MA043168A patent/MA43168A/fr unknown
- 2016-11-04 AU AU2016348524A patent/AU2016348524B2/en not_active Ceased
- 2016-11-04 CA CA3001873A patent/CA3001873A1/en not_active Abandoned
- 2016-11-04 US US15/773,915 patent/US11033539B2/en active Active
- 2016-11-04 HK HK18112407.2A patent/HK1253029A1/zh unknown
- 2016-11-04 BR BR112018008630A patent/BR112018008630A2/pt not_active IP Right Cessation
- 2016-11-04 MX MX2018005215A patent/MX386148B/es unknown
- 2016-11-04 ES ES16798333T patent/ES2915266T3/es active Active
- 2016-11-04 MY MYPI2018000570A patent/MY194461A/en unknown
- 2016-11-04 WO PCT/US2016/060659 patent/WO2017079641A1/en not_active Ceased
- 2016-11-04 PE PE2018000730A patent/PE20181010A1/es unknown
-
2018
- 2018-04-23 IL IL258862A patent/IL258862B/en active IP Right Grant
- 2018-05-02 PH PH12018500940A patent/PH12018500940A1/en unknown
- 2018-05-04 CL CL2018001217A patent/CL2018001217A1/es unknown
- 2018-05-04 CO CONC2018/0004800A patent/CO2018004800A2/es unknown
- 2018-05-05 SA SA518391518A patent/SA518391518B1/ar unknown
-
2021
- 2021-01-05 JP JP2021000354A patent/JP2021050243A/ja not_active Withdrawn
- 2021-04-26 US US17/239,726 patent/US20210338653A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018008630A2 (pt) | 2018-10-30 |
| MX2018005215A (es) | 2018-08-01 |
| AU2016348524B2 (en) | 2021-01-28 |
| US20210338653A1 (en) | 2021-11-04 |
| HK1253029A1 (zh) | 2019-06-06 |
| CO2018004800A2 (es) | 2018-10-31 |
| US11033539B2 (en) | 2021-06-15 |
| EP3371164B1 (en) | 2022-03-16 |
| CN108349936B (zh) | 2021-10-01 |
| JP2018531981A (ja) | 2018-11-01 |
| KR20180073685A (ko) | 2018-07-02 |
| JP6917989B2 (ja) | 2021-08-11 |
| CA3001873A1 (en) | 2017-05-11 |
| PH12018500940A1 (en) | 2018-12-17 |
| IL258862A (en) | 2018-06-28 |
| AU2016348524A1 (en) | 2018-05-17 |
| PE20181010A1 (es) | 2018-06-26 |
| SA518391518B1 (ar) | 2021-06-13 |
| EP3371164A1 (en) | 2018-09-12 |
| MX386148B (es) | 2025-03-18 |
| US20180325887A1 (en) | 2018-11-15 |
| WO2017079641A1 (en) | 2017-05-11 |
| SG11201803757UA (en) | 2018-06-28 |
| MY194461A (en) | 2022-11-30 |
| CN108349936A (zh) | 2018-07-31 |
| ES2915266T3 (es) | 2022-06-21 |
| MA43168A (fr) | 2018-09-12 |
| CL2018001217A1 (es) | 2018-08-03 |
| IL258862B (en) | 2021-02-28 |
| JP2021050243A (ja) | 2021-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2018000130A1 (en) | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
| MX2020002060A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos. | |
| CR20210001A (es) | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2) | |
| MY199103A (en) | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists | |
| MX2021009763A (es) | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. | |
| SG10201902206QA (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
| PH12012501800A1 (en) | 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| HK1231471A1 (zh) | 6-杂芳氧基-和6芳氧基-喹啉-2-甲酰胺及其用途 | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| WO2016012965A3 (en) | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof | |
| MX354175B (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria. | |
| MX353209B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
| NZ721645A (en) | Compounds for use as gpr120 agonists | |
| WO2020081410A3 (en) | Radioligands for imaging the lpa1 receptor | |
| SG10201806809QA (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| EA201891682A1 (ru) | Производное азациклического амида, способ его получения и фармацевтическое применение | |
| EA200702612A1 (ru) | Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт | |
| MX2018015990A (es) | Compuestos terapeuticos. | |
| WO2015187850A3 (en) | Compounds and methods for treatment of ocular disorders | |
| EA201891038A1 (ru) | Антагонисты мускаринового рецептора 4 и способы их применения | |
| EA202090644A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3K | |
| EA202091472A1 (ru) | Триазол-азины циклогексиловой кислоты как антагонисты lpa | |
| EA202090176A1 (ru) | Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида | |
| UA109736C2 (uk) | Поліморфна форма мезилатної солі 2-(2,4,5-заміщеного аніліно)піримідину (варіанти) |